Are certain forms of the P2Y2 gene associated with the risk of stroke in northern Han Chinese people?

Submission date	Recruitment status	Prospectively registered		
15/10/2018	No longer recruiting	[_] Protocol		
Registration date	Overall study status	[] Statistical analysis plan		
24/10/2018	Completed	[X] Results		
Last Edited 13/12/2018	Condition category Circulatory System	Individual participant data		

Plain English summary of protocol

Background and study aims

People in northern China are at an increased risk of ischemic stroke (damage to the brain caused by narrowing of blood vessels in the brain). This study aimed to investigate if gene forms linked to increased risk of stroke are more common in Han Chinese people in this region.

Who can participate?

People aged 45-80 years who had had an ischemic stroke and healthy volunteers matched in terms of age, gender, ethnic group and area of residence with the stroke group.

What does the study involve? One sample of blood was taken from a vein (usually in the arm).

What are the possible benefits and risks of participating? There was the potential for discomfort when the blood was taken. There are no potential benefits of taking part.

Where is the study run from? The First Affiliated Hospital of China Medical University.

When is the study starting and how long is it expected to run for? The samples were collected from September 2010 to May 2011 and the data analysed from March 2012 to April 2012.

Who is funding the study? This study was supported by a grant from the National Natural Science Foundation of China, No. 81070913.

Who is the main contact? Zhi-yi He Hezhiyi0301@sina.com

Contact information

Type(s) Public

Contact name Dr Li-Ying Yuan

Contact details No.155, Nanjing North Street, Heping District Shenyang China 110000 13998250891 cmu_jane@sina.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 1.0

Study information

Scientific Title

G-Protein Coupled Purinergic Receptor P2Y2 (P2RY2) gene rs4944832 polymorphism increases the risk of ischemic stroke in the northern Han Chinese population

Study objectives

The G-C-G haplotype of P2RY2 is a susceptibility haplotype for ischemic stroke. In addition, the GG genotype of rs4944832 may be associated with the development of small-artery occlusion in the northern Han Chinese population.

Ethics approval required

Old ethics approval format

Ethics approval(s)

 Ethics Committee of the First Affiliated Hospital of China Medical University, 20/02/2012, 2012-38-1
Ethics Committee of the First Affiliated Hospital of Liaoning Medical University, 01/03/2013, 2013-03-1

Study design

Observational case-control study

Primary study design

Observational

Secondary study design Case-control study

Study setting(s) Hospital

Study type(s) Screening

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Ischemic stroke

Interventions

In this study, clinical data and peripheral blood specimens were collected from ischemic stroke patients and controls. The ischemic stroke participants were recruited from the First Affiliated Hospital of China Medical University and the First Affiliated Hospital of Liaoning Medical University. The controls were recruited from the Health Check Center at the First Affiliated Hospital of China Medical University. Ischemic stroke patients were divided into two subgroups according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification: large-artery atherosclerosis (n = 178) and small-artery occlusion (n = 200) strokes. All subjects were genotyped using SNaPshot® Multiplex (Thermo Fisher Scientific) for three single-nucleotide polymorphisms in the P2RY2 gene (rs4944831, rs1783596 and rs4944832) in peripheral venous blood.

Intervention Type

Genetic

Primary outcome measure

The genotype frequencies of the three P2RY2 SNPs (rs4944831, rs1783596, and rs4944832) in ischemic stroke patients and controls.

Secondary outcome measures

1. Allele frequencies of the three P2RY2 SNPs (rs4944831, rs1783596, and rs4944832) in ischemic stroke patients and controls.

2. Inferred haplotypes of these three P2RY2 SNPs (rs4944831, rs1783596, and rs4944832).

Overall study start date

01/05/2010

Completion date 30/04/2012

Eligibility

Key inclusion criteria

Inclusion criteria for the ischemic stroke group:

1. According to the TOAST classification, patients in the ischemic stroke group were diagnosed depending on clinical features and neuroimaging criteria that included the sudden onset of a global or focal neurological deficit, with corresponding brain infarction as seen on computed tomography (CT) imaging or magnetic resonance imaging (MRI) (Adams et al., 1993). Examinations of cerebral blood vessels, such as computed tomography angiography and magnetic resonance angiography, were performed when necessary.

Inclusion criteria for the control group:

1. Unrelated healthy controls with no clinical or radiological evidence of stroke or cerebrovascular diseases.

2. Some healthy controls had vascular risk factors such as hypertension, diabetes, smoking, drinking, and hypercholesterolemia.

Participant type(s)

Mixed

Age group

Adult

Sex

Both

Target number of participants

722

Key exclusion criteria

Exclusion criteria for the ischemic stroke group:

- 1. Cancer
- 2. Hemorrhagic stroke
- 3. Transient ischemic attack
- 4. Severe cardiac, hepatic, or renal diseases

Exclusion criteria for control subjects:

- 1. Cancer
- 2. Autoimmune disease
- 3. Chronic inflammation
- 4. Renal insufficiency
- 5. Liver insufficiency
- 6. Hematopathy

Date of first enrolment

01/09/2010

Date of final enrolment 30/05/2011

Locations

Countries of recruitment China

Study participating centre The First Hospital of China Medical University No.155, Nanjing North Street, Heping District Shenyang

China 110000

Study participating centre The First Affiliated Hospital of Liaoning Medical University No.2, Section 5, Renmin Street, Guta District Jinzhou China 121000

Sponsor information

Organisation the First Hospital of China Medical University

Sponsor details

No.155, Nanjing North Street, Heping District Shenyang China 110000 86-024-961200 ydyyyzxx@126.com

Sponsor type Hospital/treatment centre

ROR https://ror.org/04wjghj95

Funder(s)

Funder type Government

Funder Name

National Natural Science Foundation of China

Alternative Name(s)

Chinese National Science Foundation, Natural Science Foundation of China, National Science Foundation of China, NNSF of China, NSF of China, , National Nature Science Foundation of China, Guójiā Zìrán Kēxué Jījīn Wěiyuánhuì, NSFC, NNSF, NNSFC

Funding Body Type Government organisation

Funding Body Subtype National government

Location China

Results and Publications

Publication and dissemination plan

Intention to publish date 17/04/2019

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Results article</u>	results	01/03/2019		Yes	No